Phase1, Placebo-Controlled, Randomized, Double-blind, Single-ascending Dose Study in Healthy Subjects.

Exclusion Criteria

• •1. Any clinically significant abnormality or abnormal laboratory test results found during medical screening or positive test for hepatitis B, hepatitis C, or HIV found during medical screening.
• •2. Positive urine drug screen or urine cotinine test at screening.
• •3. Current cigarette smokers or former smokers with a smoking history of greater than 5 pack years or who stopped smoking within the 2 years preceding enrolment in the study. For the determination of pack years, a pack of cigarettes is assumed to contain 20 cigarettes.
• •4. History of significant allergic reactions (e.g. angioedema, anaphylactic reactions).
• •5. History of panic disorder or panic attacks
• •6. Positive pregnancy test at screening.
• •7. Any reason which, in the opinion of the Investigator (or delegate), would prevent the subject from participating in the study.
• •8. Clinically significant electrocardiogram (ECG) abnormalities or vital sign abnormalities (systolic blood pressure lower than 90 or over 140 mmHg, diastolic blood pressure lower than 50 or over 90 mmHg, or heart rate less than 50 or over 100 bpm) at screening.
• •9. History of significant alcohol abuse within one year prior to screening or regular use of alcohol within six months prior to the screening visit (more than fourteen units of alcohol per week \[1 Unit = 150 mL of wine, 360 mL of beer, or 45 mL of 40% alcohol\]) or positive alcohol breath test at screening.
• •10. History of significant drug abuse within one year prior to screening or use of soft drugs (such as marijuana) within 3 months prior to the screening visit or hard drugs (such as cocaine, phencyclidine \[PCP\], and crack) within 1 year prior to screening.
• •11. Use of an investigational drug within 30 days (90 days for biologics) or participation in an investigational study within 30 days prior to dosing.
• •12. Use of anticoagulants, immunosuppressives, regular use of non-steroidal anti-inflammatory drugs, use of anti-IgE medication, or any allergen specific immunotherapy within the last 60 days.
• •13. Use of medication other than non-steroidal topical products without significant systemic absorption:
• •* prescription medication (other than the ones listed previously) within 14 days prior to the first dosing;
• •* over-the-counter products including natural health products (e.g. food supplements and herbal supplements) within 7 days prior to the first dosing, with the exception of the occasional use of acetaminophen (up to 2 g daily);
• •* a depot injection or an implant of any drug within 3 months prior to the first dosing.
• •* monoamine oxidase (MAO) inhibitors within 30 days prior to the first dosing.
• •14. Donation of blood within 7 days prior to dosing. Donation or loss of blood (excluding volume drawn at screening) of 50 mL to 499 mL of blood within 30 days, or more than 499 mL within 56 days prior to dosing.
• •15. Hemoglobin \<128 g/L (males) and \<115 g/L (females) and hematocrit \<0.37 L/L (males) and \<0.32 L/L (females) at screening.
• •16. Breast-feeding subject.
• •17. History of wheezing after exercise
• •18. History of or previous medical diagnosis of asthma